
# Lonza


# Metabolic Research Tools for Biologically Relevant Results



# Avoid Research Roadblocks and Take a Direct Route to Results



2



"How can I optimize my diabetic drug leads?"

SOLUTION: Lonza can ease your drug discovery research with our advanced cell culture tools such as 3D culture systems and Cells on Demand<sup>™</sup> Cell Culture Services. **Page 10** 

# Drug Discovery

"I can't find reliable assay tools for protein expression, cell proliferation, or adipogenic cell studies."

SOLUTION: Now you can choose from a range of molecular biology reagents and assays developed specifically for diabetes and metabolic disorders. **Page 19** 

Media

Media

– PGM™ 2 Preadipocyte Growth Media
 – ADSC Growth and Differentiation

– HCM™ Hepatocyte Culture Media

## Your Diabetes and Metabolic Toolkit

Streamline your workflow by choosing from convenient, innovative research tools that have been designed and tested to work together. Lonza gives you what you need for biologically relevant results, from high-quality primary cells, through efficient transfection technology, to a wide range of analysis tools.

| Primary<br>Cells and Media  | Transfection   | Drug Discovery   | Cell Analysis   |
|---|--|--|---|
| Normal and diabetic cryopreserved<br>primary human cells:<br>Diabetic and normal human donor<br>cell types:<br>– Aortic smooth muscle and<br>endothelial cells<br>– Coronary artery smooth muscle<br>and endothelial cells<br>– Pulmonary artery smooth muscle<br>and endothelial cells<br>– Cardiac and dermal microvascular<br>endothelial cells<br>– Cardiac and dermal microvascular<br>endothelial cells<br>– Renal proximal tubule epithelial<br>cells<br>– Adult epidermal keratinocytes<br>– Skeletal muscle myoblasts<br>– Preadipocytes, subcutaneous<br>and visceral<br>– Adult adipose derived stem cells<br>Other normal human donor<br>cell types:<br>– Pancreatic Islets via<br>Cells on Demand <sup>®</sup> Service<br>– Renal cortical epithelial cells<br>– Renal epithelial cells<br>– Mesangial cells | Nucleofector <sup>™</sup> Technology with<br>optimized protocols for primary cells<br>including:<br>- Endothelial cells, such as<br>aortic and coronary artery<br>- Epithelial cells, such as human<br>kidney epithelial cells<br>- Smooth muscle cells, such as<br>aortic smooth muscle<br>- Rat, mouse and human<br>hepatocytes<br>- Human preadipocytes<br>Also optimized for many cell lines,<br>including:<br>- Hep G2<br>- Capan-1<br>- HCT 116<br>- Ins-1<br>- Min6<br>- MDCK | RAFT 3D Cell Culture System<br>- Cancer Research<br>- Dermal Research<br>- Corneal Models<br>- Blood Brain Barrier Models<br>Conditionally immortalized<br>human cell lines:<br>- Preadipocytes<br>- Skeletal Muscle Cells<br>- Dermal Fibroblasts<br>- Coronary Artery Smooth Muscle<br>Cells (CASMC)<br>- Blood (BEC) and Lymphatic (LEC)<br>Microvascular Endothelial Cells<br>- Adult Dermal Keratinocytes<br>- Brain Microvascular Endothelial<br>Cells<br>Biowhittaker" Liquid and<br>Powder Media for therapeutic<br>and research needs<br>Cells on Demand" Services:<br>- Custom transfection services | <ul> <li>Cell proliferation and cytotoxicity<br/>bioassay kits:         <ul> <li>ViaLight<sup>®</sup> Kit for measuring cell<br/>proliferation and cytotoxicity</li> <li>ToxiLight<sup>®</sup> Kit for non-destructive<br/>measurement of cytotoxicity</li> </ul> </li> <li>Cell function assays:         <ul> <li>Bone mineralization and resorption<br/>assays</li> <li>Adipogenesis and lipolysis mea-<br/>surement assays</li> </ul> </li> <li>Mycoplasma detection:             <ul> <li>MycoAlert<sup>®</sup> Assay for accurate,<br/>reliable and universal mycoplasma<br/>detection</li> </ul> </li> <li>DNA, RNA, and protein expression<br/>analysis:             <ul> <li>PAGEr<sup>®</sup> EX Gels and ProSieve<sup>®</sup> EX<br/>Reagents for protein analysis and<br/>Western blotting</li> <li>FlashGel<sup>®</sup> System for PCR analysis<br/>and RNA integrity analysis</li> </ul> </li> </ul> |
| Optimized Clonetics <sup>™</sup> Primary Cell<br>Growth Media:<br>— EGM <sup>™</sup> 2 Endothelial Growth Media<br>— SmGM <sup>™</sup> 2 Smooth Muscle Growth<br>Media<br>— REGM <sup>™</sup> Renal Growth Media<br>— MsGM <sup>™</sup> Mesangial Growth Media<br>— KGM <sup>™</sup> Gold Keratinocyte Growth   |  |  | and affordable live cell imaging<br>system for documentation or<br>monitoring of cell cultures  |

4

# Primary Cells and Media


Choose from a wide range of high-quality primary, non-transformed, nonimmortalized cells from Lonza. They have all been tested and matched with media to save you the time and effort of optimization.


More than 20% of cell culture studies are based on misidentified or crosscontaminated cell lines. Lonza's products have been developed to give you complete confidence in your results.

Our cells have been sourced from a variety of donors, including those diagnosed with diabetes type I and diabetes type II.

"I'm uncertain of the results that I get from genetically modified cell lines."

SOLUTION: Simulate *in vivo* research in culture by choosing from our comprehensive selection of primary cells.





Human skeletal muscle myoblasts, differentiated and immunostained with desmin, counterstained with DAPI

### Clonetics<sup>™</sup> Diabetic Cells

Enhance the relevance of your results by working with human primary cells that have been isolated from diabetes type I and II donors:

- Compare diseased cells to normal primary cells for a better understanding of effects
- To learn more about cell donors, contact our scientific support team
- All cells test negative for bacterial, fungal, and mycoplasma contamination
- Human cells test negative for HIV-1, Hepatitis-B, and Hepatitis-C

Diabetic human cells include:

- Aortic smooth muscle cells
- Coronary artery smooth muscle cells
- Pulmonary artery smooth muscle cells
- Aortic endothelial cells
- Coronary artery endothelial cells
- Pulmonary artery endothelial cells
- Cardiac microvascular endothelial cells
- Dermal microvascular endothelial cells
- Renal proximal tubule epithelial cells
- Adult epidermal keratinocytes
- Skeletal muscle myoblasts
- Preadipocytes, subcutaneous and visceral
- Adult adipose derived stem cells

For best results, match these cells with our optimized Clonetics<sup>™</sup> Media BulletKits<sup>™</sup>.

### Normal Human Cells

#### Pancreatic Cells

- Fresh human pancreatic islets

#### Smooth Muscle Cells

- Aortic smooth muscle cells
- Coronary artery smooth muscle cells
- Pulmonary artery smooth muscle cells

#### Endothelial Cells from Large Vessels

- Aortic endothelial cells
- Coronary artery endothelial cells
- Pulmonary artery endothelial cells
- Iliac artery endothelial cells
- Umbilical vein endothelial cells, single and pooled
- Umbilical Vein endothelial cells, expanded

#### Endothelial Cells from Small Vessels

- Cardiac microvascular endothelial cells
- Dermal microvascular endothelial cells, adult and neonatal
- Dermal lymphatic microvascular endothelial cells, adult and neonatal
- Lung blood microvascular endothelial cells
- Lung microvascular endothelial cells
- Lung lymphatic microvascular endothelial cells

#### **Renal Cells**

- Renal proximal tubule epithelial cells
- Renal cortical epithelial cells
- Renal epithelial cells
- Mesangial cells

#### Intestinal Cells

- Myofibroblasts
- Epithelial cells

#### Dermal Cells

- Adult epidermal keratinocytes
- Neonatal epidermal keratinocytes, single and pooled donors

#### **Skeletal Muscle Cells**

- Skeletal muscle myoblasts
- Skeletal muscle cells

#### Adipose Cells

- Preadipocytes, subcutaneous and visceral
- Adult adipose derived stem cells

### Clonetics<sup>™</sup> Media BulletKits<sup>™</sup>

- EGM<sup>™</sup> 2 Endothelial Growth Media
- SmGM<sup>™</sup> 2 Smooth Muscle Growth Media
- REGM™ Renal Growth Media
- MsGM™ Mesangial Growth Media
- KGM<sup>™</sup> Gold Keratinocyte Growth Media
- PGM<sup>™</sup> 2 Preadipocyte Growth Media
- ADSC Growth and Differentiation Media
- HCM<sup>™</sup> Hepatocyte Culture Media
- You can find recommended media with the Ordering Information on page 24.

### Primary Cells for Validation of Cell Line Results

Find the metabolism-related cell line you're working with below and the related primary cell type to validate those results.

| Cell Line  | Recommended Primary Cell from Lonza   |
|--|---|
| 3T3-L1<br>mouse fibroblast   | Human preadipocytes, visceral<br>or subcutaneous  |
| L6 and C2C12<br>Rat muscle myoblast cell line and<br>mouse muscle myoblast cell line   | Primary human skeletal muscle myoblasts   |
| <b>Caco-2</b><br>Human intestinal epithelial cell line   | Primary human intestinal myofibroblasts and epithelial cells  |
| ECV-304<br>(This line was originally thought to be<br>from a spontaneously-transformed<br>line derived from a Japanese human<br>umbilical vein endothelial cells<br>however it was found to be human<br>bladder cancer derived epithelial cell<br>line T24/83) | Primary human umbilical vein<br>endothelial cells (HUVEC)   |
| INS-1, RIN5F, MIN6   | Rat and mouse cell lines as substitutes for beta cells  |
| Others   | Call Lonza scientific support for additional primary cell types that match your need for biological relevance |

# Primary Cell Case Study: Adipogenesis and Lipolysis in Differentiated Human Subcutaneous Adipocytes

Measuring adipogenesis and lipolysis in human subcutaneous adipocytes using new sensitive, biochemical assays Marjorie Smithhisler and Huan Tran from Lonza Walkersville, Inc., USA

### Summary

The physiological functions associated with fat metabolism are still being elucidated. However, it is known that the accumulation and break-down of triglycerides cause widespread systemic effects. Two most commonly studied sources of adipocytes are from visceral and subcutaneous fat tissue. Subcutaneous fat is often found attached to skin in the lower abdomen area. Visceral Preadipocytes are isolated from adipose tissue associated with internal organs, such as the bladder or kidney. Relative to subcutaneous fat, visceral fat deposits are mobilized at a higher rate to produce fatty acids that contribute to insulin resistance, Diabetes Type 2, and other related cardiovascular disorders. Measuring the increase and break-down of intracellular triglycerides into free fatty acids and glycerol within adipocytes is important to discovering new cures for a myriad of metabolic disorders.

### **Methods and Materials**

Subcutaneous and visceral preadipocytes (Lonza) were grown and differentiated per cell system instructions in PGM<sup>™</sup> 2 Preadipocyte Growth Medium at 37°C, 5% CO<sub>2</sub>. Differentiation media was added and cells were monitored for lipid accumulation over 10 days. Cells were then stained with AdipoRed<sup>™</sup> Adipogenesis Assay Reagent. Cells were induced to undergo lipolysis via the addition of 1 µM isoproterenol and induction was tested for insulin inhibition with 10 µg/mL insulin addition. Cell supernatants were diluted and tested with the AdipoLyze<sup>™</sup> Lipolysis Detection Assay for glycerol accumulation. For more detailed information about the cells, assays, or lipolysis induction contact Lonza scientific support.

### Results

Subcutaneous and visceral preadipocytes both showed marked lipid accumulation after 10 days via AdipoRed<sup>™</sup> Staining (Figure 1, quantitative plate reader results not shown). Both cell types showed increased levels of lipolysis in the differentiated cultures versus undifferentiated cultures as determined by AdipoLyze<sup>™</sup> assay, which measures extracellular release of glycerol, a by-product of triglyceride breakdown. Both cultures showed lipolysis inhibition by the addition of insulin (Figure 2, subcutaneous data only shown here).

### Conclusions

In summary, primary visceral and subcutaneous preadipocytes showed both the accumulation and breakdown of intracellular lipid, and these two processes were adequately measured via AdipoRed<sup>™</sup> and AdipoLyze<sup>™</sup> cell-based assays. The cells, media and assays can be used congruently to study certain metabolic changes *in vitro* research studies.





Figure 1. Subcutaneous (top) and visceral (bottom) preadipocytes (undifferentiated, left column, differentiated, right column) stained with AdipoRed<sup>®</sup> assay reagent.



Quantified Glycerol Release by Differentiated Subcutaneous Adipocytes

Figure 2. AdipoLyze™ Lipolysis Detection Assay results for glycerol accumulation in subcutaneous preadipocytes.

# Transfection

You can deliver almost any substrate – such as plasmid DNA, siRNA, shRNA, or peptides – to primary cells and hard-to-transfect cell lines with our non-viral Nucleofector<sup>™</sup> Technology.

This improved technique will play an increasingly important role in delivering genes to primary smooth muscle, epithelial, and endothelial cells.

### Nucleofector<sup>™</sup> Technology

Transfect primary cells and cell lines related to metabolic diseases with up to 90% efficiency while maintaining excellent cell viability. Nucleofection™ allows you to:

- Use validated transfection protocols for 13 primary cells related to metabolic diseases
- Select optimized transfection conditions for more than 30 cell lines related to metabolic diseases
- Easily establish Nucleofection<sup>™</sup> conditions for other mammalian cells using our cell primary cell or cell line optimization protocols

" I can't transfect my primary cells or cell lines of interest efficiently."

SOLUTION: Our Nucleofector<sup>™</sup> Technology delivers up to 90% gene transfection efficiency, at high viability and maintenance of functionality.



- Use the same transfection conditions for different cell numbers and volumes
- Select from a range of platforms to suit your cell number and throughput needs

#### Choose the Nucleofector™ Platform that Suits Your Research Needs

|  | Advanced Platform                                 | 96-Well Add-On                     | High-Throughput Platform           | Basic Device                               |
|--|---|------------------------------------|------------------------------------|--|
| Device   | 4D-Nucleofector™ System                           | 96-well Shuttle™ System            | 384-well Nucleofector™ System      | Nucleofector™ 2b Device                    |
|  |   |                                    | LORID                              |  |
| Unit   |   |                                    |                                    |  |
| Throughput (samples per run)                       | Low to medium (1 – 16)                            | Low to high (1 – 96)               | High (384)                         | Low (1)                                    |
| Reaction volume                                    | 20 µL + 100 µL                                    | 20 µL                              | 20 µL                              | 100 µL                                     |
| Electrode material                                 | Conductive polymer                                | Conductive polymer                 | Conductive polymer                 | Aluminum                                   |
| Low cell numbers (20 µL)                           | $5 \times 10^4$ to $1 \times 10^5$                | $5 \times 10^4$ to $1 \times 10^5$ | $5 \times 10^4$ to $1 \times 10^5$ | _  |
| High cell numbers (100 µL)                         | $2 \times 10^5$ to $2 \times 10^6$                | _                                  | _                                  | 2 × 10 <sup>5</sup> to 2 × 10 <sup>6</sup> |
| DNA vector amount/sample                           | 0.2 — 1 µg (20 µL)<br>1 — 5 µg (100 µL)           | 0.2 – 1 µg                         | 0.2 – 1 µg                         | 1 – 5 µg                                   |
| siRNA amount/sample<br>(concentration 2 nM – 2 μM) | 0.04 – 40 pmol (20 µL)<br>0.2 – 200 pmol (100 µL) | 0.04 – 40 pmol                     | 0.04 – 40 pmol                     | 0.2 – 200 pmol                             |
| Compatibility with<br>96-well Shuttle™ System      |   | _                                  | _                                  |  |

🕮 www.lonza.com/celldatabase – To find transfection data for your cell type of interest.

#### Transfection Efficiency and Cell Viability with Nucleofector™ Technology

|  | Efficiency* | Viability* | Kit for 4D-Nucleofector™ and 96-Well<br>Shuttle™ Systems (Name of Specific Protocol) | Kit for Nucleofector™ II/2b Device         |
|--|-------------|------------|--|--|
| Smooth Muscle Cells                                |             |            |  |  |
| SMC, aortic (AoSMC), human                         | 75-80%      | 55-95%     | P1 Primary Cell Kit (AoSMC)  | AoSMC Nucloefector <sup>™</sup> Kit        |
| SMC, coronary artery (CASMC), human                | 60-70%      | 80-90%     | P1 Primary Cell Kit (smooth muscle cell, basic)                                      | Basic Smooth Muscle Cell Nucloefector™ Kit |
| SMC, pulmonary artery (PASMC), human               | 75-85%      | 60-70%     | P1 Primary Cell Kit (smooth muscle cell, basic)                                      | Basic Smooth Muscle Cell Nucloefector™ Kit |
| Endothelial Cells, Large Vessels                   |             |            |  |  |
| Aortic endothelial cells, human                    | 55-75%      | 45-60%     | P5 Primary Cell Kit (endothelial cell, basic)  | Basic Endothelial Cell Nucloefector™ Kit   |
| Coronary artery endothelial cells, human           | 50-60%      | 75-100%    | P5 Primary Cell Kit (endothelial cell, basic)  | HCAEC Nucloefector™ Kit                    |
| Endothelial, umbilical vein, human (HUVEC)         | 80-90%      | 55-75%     | P5 Primary Cell Kit (HUVEC)  | HUVEC Nucloefector™ Kit                    |
| Endothelial Cells, Small Vessels                   |             |            |  |  |
| Dermal microvascular endothelial cells, human      | 64%         | 99%        | P5 Primary Cell Kit (endothelial cell, basic)  | Basic Endothelial Cell Nucloefector™ Kit   |
| Lung microvascular endothelial cells, human        | 79%         | 48%        | P5 Primary Cell Kit (endothelial cell, basic)  | HMVEC-L Nucloefector™ Kit                  |
| Renal Cells  |             |            |  |  |
| Mesangial cells, human                             | 83%         | 81%        | Primary Cell Optimization Kit  | Basic Smooth Muscle Cell Nucloefector™ Kit |
| Intestinal Cells                                   |             |            |  |  |
| Myofibroblasts, human                              | 57%         | no data    | P2 Primary Cell Kit (fibroblast, basic)  | Basic Fibroblast Nucloefector™ Kit         |
|  |             |            | P3 Primary Cell Kit (fibroblast, basic)  |  |
| Dermal Cells                                       |             |            |  |  |
| Adult epidermal keratinocytes, human               | 60%         | 62%        | P3 Primary Cell Kit (adult keratinocytes)  | Human Keratinocyte Nucleofector™ Kit       |
| Neonatal epidermal keratinocytes, human            | 63%         | 67%        | P3 Primary Cell Kit (adult keratinocytes)  | Human Keratinocyte Nucleofector™ Kit       |
| Adipose Cells                                      |             |            |  |  |
| Preadipocytes, subcutaneous and visceral,<br>human | 33-92%      | 42-81%     | P1 Primary Cell Kit  | Basic Fibroblast Nucloefector™ Kit         |
| Adult adipose derived stem cells, human            | 73-84%      | 58-85%     | P1 Primary Cell Kit  | Human MSC Nucleofector™ Kit                |
| Hepatocytes  |             |            |  |  |
| Hepatocytes human                                  | 54%         | 59-69%     | P3 Primary Cell Kit (hepatocytes, human)   | Contact scientific support for guidance    |
| Hepatocytes, mouse                                 | 54%         | 80%        | Primary Cell Optimization Kit  | Mouse/Rat Hepatocyte Nucleofector™ Kit     |
| Hepatocytes, rat                                   | 52%         | 78%        | Primary Cell Optimization Kit  | Mouse/Rat Hepatocyte Nucleofector™ Kit     |
| Kidney/Renal Related Cell Lines**                  |             |            |  |  |
| MDCK   | 83-98%      | 51-95%     | SE Cell Line Kit   | Cell Line L                                |
| BHK-21   | 85%         | 78%        | SE Cell Line Kit   | Cell Line L                                |
| Pancreas Related Cell Lines**                      |             |            |  |  |
| Min6   | 60-75%      | 40-80%     | Cell Line Optimization Kit   | Cell Line T                                |
| Ins-1  | 70-90%      | 75-85%     | Cell Line Optimization Kit   | Cell Line T                                |
| Capan-1  | 29-67%      | 40-78%     | SE Cell Line Kit   | Cell Line V                                |
| Gastro Intestinal Related Cell Lines               | **          |            |  |  |
| Colo201  | 57%         | 78-96%     | Cell Line Optimization Kit   | Cell Line R                                |
| HCT 116  | 78-94%      | 61-76%     | SE Cell Line Kit   | Cell Line V                                |
| Liver Related Cell Lines                           |             |            |  |  |
| Hep-G2   | 72-95%      | 92%        | SF Cell Line Kit   | Cell Line V                                |
|  |             |            |  |  |

Primary cells marked **blue** have Lonza-validated optimized protocols.

 ${}^{*}\!\mathsf{Approximate ranges extrapolated from larger result collections, including Lonza and customer data$ 

\*\*This is only a selection of cell lines. 🌐 www.lonza.com/celldatabase – For further cell lines and protocol guidance.

# Drug Discovery

Our dedicated drug discovery team gives you access to Lonza's expertise in many areas of cell biology. We trust that we have identified the products and services of value to drug discovery customers and we welcome the opportunity to discuss and develop them further with you.

### RAFT<sup>™</sup> 3D Cell Culture System

3D cell culture differs significantly from the traditional 2D culture that most researchers have been using since the past decades. There is a trending shift both in academia and industry to personalized research solutions and more *in vivo* like models to understand cell behavior. This is fueling the growing market need for better solutions in 3D cell culture such as RAFT<sup>m</sup> 3D Cell Culture System.

An important differentiation of the RAFT<sup>™</sup> System to other 3D platforms or to 2D culture methods is its ability to engineer tissue-like 3D cultures. This is especially needed for certain applications such as development of *in vitro* liver fibrosis models or corneal models. With RAFT<sup>™</sup> System, cells can be cultured within a **high-density** collagen scaffold, or on top, or both. The addition of permeable membrane cell culture inserts provides other extensions to the system allowing the generation of barrier models including air-lift models.

RAFT<sup>™</sup> Cultures can be created in less than an hour using simple protocols and standard labware! RAFT<sup>™</sup> Kits are available in a choice of 24-well, insert-well and 96-well formats. RAFT<sup>™</sup> System has already been used to successfully generate 3D cultures in a number of research areas including oncology, toxicology, barrier modeling, dermal research and pulmonary research.

Contact your local sales representative to learn how RAFT<sup>™</sup> System can support your experiments.

"How can l optimize my diabetic drug leads?"

SOLUTION: Lonza can ease your drug discovery research with our advanced cell culture tools such as 3D culture systems and Cells on Demand<sup>™</sup> Cell Culture Services.





Figure 1. RAFT™ 3D Culture System consists of RAFT™ Reagent Kit and Absorbers for 96-well, 24-well and trans-well inserts.



Figure 2. Dermal fibroblasts fixed and stained after 11 days in RAFT™ System.



Figure 3. Sample acellular RAFT<sup>™</sup> Cultures in a vial showing high-density collagen scaffolds.

# Fluorescence Microscopy-based Characterization of Cells Grown in RAFT<sup>™</sup> 3D Culture

By Cecile Villemant<sup>1</sup>, Grant Cameron<sup>1</sup>, Lubna Hussain<sup>2</sup>, Jenny Schroeder<sup>3</sup>

<sup>1</sup>TAP-Biosystems, Royston, UK; <sup>2</sup>Lonza Walkersville, Inc., Walkersville, MD, USA; <sup>3</sup>Lonza Cologne GmbH, Koeln, Germany

### Introduction

*In vitro* assays typically use cells grown on two-dimensional (2D) hard plastic or glass substrates, which are not representative of the true *in vivo* cell environment.<sup>1</sup> In tissue, cells interact with neighboring cells and with the extracellular matrix (ECM). In a simplified *in vitro* 2D environment, most of the tissue-specific architecture, cell-cell communication and cues are lost. Therefore, the need exists for advanced culture methods that better mimic cellular function within living tissue.

Three-dimensional (3D) cell culture methods, in comparison, provide a matrix that encourages cells to organize into structures more indicative of the *in vivo* environment, thereby developing normal cell-cell and cell-ECM interactions in an *in vitro* environment.

The RAFT<sup>™</sup> 3D Culture System (Figure 1) uses a collagen matrix at physiologically relevant concentrations. Cells and neutralized collagen are mixed and dispensed into wells of standard cell culture plates, and subsequently incubated at 37°C to allow the formation of a cell-seeded hydrogel. Specialized RAFT<sup>™</sup> Absorbers are placed on top of the hydrogels. The RAFT<sup>™</sup> Absorbers gently remove the medium, thus concentrating the cell/collagen hydrogel to a layer approximately 120 µm thick, mimicking physiological conditions. The cultures are then ready for use. Optionally, additional collagen layers or epithelial or endothelial cell overlays may be added to study co-cultures or more complex cultures.

Assessing the viability of cells grown in a RAFT<sup>™</sup> 3D Cell Culture, or performing immunofluorescence staining, may not seem as trivial as assessing the viability of a 2D cell culture. However, here we show that by adding some basic controls, the LIVE/DEAD<sup>®</sup> Assay is a straightforward and reliable method to assess the viability of cells inside a RAFT<sup>™</sup> 3D Cell Culture. In addition, we show that immunofluorescence microscopy can be performed easily and routinely on RAFT<sup>™</sup> 3D Cell Cultures.



Figure 1. Creation of 3D cell/collagen hydrogel using the RAFT<sup>\*\*</sup> System in standard cell culture plates.

### **General Materials**

- RAFT<sup>™</sup> Absorbers and Reagent Kits, visit www.lonza.com/raft for a list of RAFT<sup>™</sup> Products and RAFT<sup>™</sup> Protocols
- For a list of recommended cell culture plates (either 96-well black wall or 24-well plate, not supplied with the kit), contact Lonza's Scientific Support Team
- Widefield fluorescence microscope with appropriate filters

### Methods

#### **Cell Culture**

Early passage primary human neonatal dermal fibroblasts (HDFs) were cultured in standard growth medium that supports dermal fibroblasts.

#### Generation of RAFT<sup>™</sup> Cultures

RAFT<sup>™</sup> Cultures were made according to the protocol supplied with the RAFT<sup>™</sup> Kits in black-walled, µClear<sup>®</sup> 96-well cell culture plates (Greiner, 655090). For the LIVE/DEAD<sup>®</sup> Assay, 3,000 HDFs per well were seeded and incubated at 37°C with 5% CO<sub>2</sub>, either overnight (1 day) or for 7 days. In addition, two acellular cultures were made for use as a background control. For immunocytochemistry, either 5,000 or 50,000 HDFs per well were seeded and then cultured for either 11 days or 3 days, respectively, prior to being fixed and stained.

### Methods continued

#### LIVE/DEAD® Assay

The LIVE/DEAD® Assay was carried out, using at least one dead control and two background controls (acellular cultures). The LIVE/DEAD® Viability/Cytotoxicity Kit (Life Technologies) was used according to the "fluorescence microscopy protocol" provided up to point 3.5. However, with the following adjustments:

- 1. To get a thorough wash of the whole 3D cell culture, the medium on the culture is aspirated and replaced with  $100 \,\mu\text{L}$  PBS and the plate left for 5–10 minutes on a rocker (while preparing the combined LIVE/DEAD® Assay Reagents).
- To prepare the dead cell sample, we incubate the cells with 1% w/v saponin for at least 30 minutes. If you have added 100 µL of medium onto your RAFT<sup>™</sup> Cultures, just add 25 µL of 5% w/v saponin 30 minnutes before performing the assay.
- 3. Due to the presence of the collagen matrix, it is advised to include acellular RAFT<sup>™</sup> 3D Cultures to act as a control for background noise.

Instead of point 4.1, onward, in the supplied LIVE/DEAD<sup>®</sup> Viability/Cytotoxicity Kit Protocol, we used the following protocol:

Aspirate the PBS, added previously from the wells, and replace it with 100  $\mu L$  of the combined LIVE/DEAD® Assay Reagents. We have found that in the case of HDFs, final concentrations of 0.4  $\mu M$  for Calcein AM and 4  $\mu M$  for Ethidium homodimer 1 (EthD-1) were optimal.

Between 10 minutes and 1.5 hours after adding the reagents, z-series at 5  $\mu$ m intervals were captured using a fluorescence microscope fitted with a z-focus drive. The numbers of live cells (stained with Calcein AM) and dead cells (stained with EthD-1) were counted from three separate images over two wells for the "live" samples. The background noise for EthD-1 was counted in two acellular cultures (bckgdEthD-1) and bckgdEthD-1). The background noise for Calcein AM was assessed in the acellular cultures and in the dead control; however, there was no visible background detected. Therefore, for each image, the percentage of viability was calculated as follows:

%viability<sub>d=1 or d=7</sub> = Number of live + dead cells - average (bckgd<sub>FthD1</sub> ①&②)

#### Immunocytochemistry

On the day of assay, the following protocol was used:

- Each RAFT<sup>™</sup> Culture was washed three times over a 15-minute period with 100 µL PBS.
- 2. The PBS was replaced with 100  $\mu L$  of 3.7% formaldehyde solution to fix the cells, and the plate incubated at room temperature for 30 minutes.
- 3. The formaldehyde solution was replaced with 100  $\mu$ L of quenching solution (1 mM Tris-HCl and 20 mM Glycine in PBS) to quench the formaldehyde cross-linking, and the plate incubated at room temperature for 10 minutes.
- 4. The RAFT<sup>™</sup> Cultures were washed as in point 1.
- 5. The PBS was replaced with 100  $\mu$ L of 0.1% Triton" X-100 solution to permeabilize the cells, and the plate was incubated at room temperature for 4 minutes.
- 6. The RAFT<sup>™</sup> Cultures were washed as in point 1.
- 7. The primary rat anti-tubulin antibody (YOL1/34; Abcam) was diluted 1:100 in 1% w/v bovine serum albumin in PBS (which was the same dilution that was optimal for cells cultured in 2D) and 50  $\mu$ L of this solution was added in each well.
- 8. The plate was then incubated overnight at 4°C.
- 9. The RAFT<sup>™</sup> Cultures were washed as in point 1.
- 10. The secondary antibody Cy3-AffiniPure Goat Anti-Rat IgG (H+L) (Stratech Scientific), phalloidin (the recommended 1/40 dilution was used) and DAPI were diluted in 1% w/v bovine serum albumin in PBS and 50  $\mu$ L of this solution was added in each well.
- 11. The plate was then incubated at room temperature for 2.5 hours.
- 12. The RAFT<sup>™</sup> Cultures were washed as in point 1.
- 13. The wells were imaged on a fluorescence widefield microscope with 100–200 ms exposure times for the anti-tubulin antibody and the phalloidin. Confocal imaging or the use of a high content imaging device would also be possible.

### Results

#### LIVE/DEAD® Assay

In Figure 2, we show the typical images that can be obtained after culturing HDFs in RAFT<sup>™</sup> 3D Cell Cultures for 1 and 7 days and staining the cultures with the combined LIVE/DEAD<sup>®</sup> Assay Reagents. We also show, in Figure 2, some examples of the Calcein AM and EthD-1 stain on an acellular construct and a dead control.




Figure 2. Examples of images that can be taken after staining RAFT<sup>™</sup> Cultures with the combined LIVE/DEAD<sup>®</sup> Assay Reagents. HDF live cells are displaying Calcein AM staining (green) while dead cells display EthD-1 staining (magenta). Each image is a projection on the z-axis of a whole z-series.

**Day 1 and Day 7:** HDFs were cultured for 1 or 7 days, respectively, in a RAFT<sup>™</sup> Plate before being treated with the combined LIVE/DEAD<sup>®</sup> Assay Reagents.

**Dead control**: HDFs cultured in RAFT" Plate for 1 day were killed using 1% w/v saponin before being stained with the combined LIVE/DEAD® Assay Reagents.

Acellular culture:  $\mathsf{RAFT}^{\bowtie}$  Acellular Culture stained with the combined LIVE/DEAD  $^{\otimes}$  Assay Reagents.

Figure 3 shows that the mean percentage viability of HDFs is 92% at Day 1 and 94% at Day 7 using the methods described above. For comparison, we have added the viability observed with the same cells cultured at the same time in a 2D planar environment, which is at 95% and 98% at Day 1 and Day 7, respectively.




Figure 3. Comparison of the viability of HDFs after 1 and 7 days in a 2D or in a RAFT™ 3D Cell Culture. The percentage viability was determined as explained in the methods above and the average for two separate experiments is shown in this graph. The standard deviation is shown for each sample.

Day of Assay and Type of Culture

#### Immunocytochemistry

After 3 days in culture, HDFs have elongated within the collagen matrix and display a typical actin and microtubule cytoskeleton as can be seen in Figures 4 and 5. The presence of the collagen matrix has little impact on the background fluorescence of the culture, in particular, when the antibodies were diluted in a BSA-containing blocking buffer.




Figure 4. HDF cells fixed and stained for tubulin and actin after being cultured in the RAFT<sup>™</sup> System for 3 days. A series of z-planes, taken at 0.5 µm intervals, was imaged on a widefield microscope after staining the RAFT<sup>™</sup> Culture for tubulin (red), actin (green) and nucleus (blue). The z-stack from each channel was projected onto one plane using the maximum z-projection function of ImageJ software and the merge of all channels is shown in the large bottom panel. Across the top panel, one frame of the z-stack is shown with each individual channel represented separately in grayscale. This represents the area boxed in the large lower panel, to better show the detail of each staining.

### **Results continued**

As shown in Figure 5, using a simple type of image deconvolution, such as ImageJ 3D parallel spectral deconvolution (http://rsb.info.nih.gov/ ij/plugins/), can help improve the sharpness of the signal and remove background noise from the cells surrounding the cell of interest (such as the blurry, out of focus cell observed above the fibroblast imaged in Figure 4). However, with our anti-tubulin antibody, images taken with our widefield microscope, and not subjected to deconvolution, were defined enough to observe microtubules within the cells in the RAFT<sup>™</sup> 3D Culture (Figure 4). Actin fibers can also be seen clearly in cells embedded in the RAFT<sup>™</sup> Collagen Matrix (Figure 4).




Figure 5. HDF cell fixed and stained for tubulin after being cultured in the RAFT" System for 11 days. One z-plane location was imaged here on a widefield microscope, after staining the RAFT" Culture for tubulin (red) and the nucleus (blue). The image from each channel was deconvolved using the 3D spectral deconvolution software from ImageJ (generalized Tikhonov) and the merge of the two channels is shown here.

### Conclusion

The LIVE/DEAD<sup>®</sup> Viability/Cytotoxicity Kit is an easy and rapid assay that can be used to assess cell viability in a RAFT<sup>™</sup> 3D Cell Culture, provided that controls are included in the test to be able to take into account the possible background noise. In this experiment, we show that HDFs display a mean viability between 92% and 94% when cultured in RAFT<sup>™</sup> 3D Culture from Day 1 and for at least 7 days, which is comparable to the viability observed for cells cultured in a 2D environment.

Cells cultured in the RAFT<sup>™</sup> 3D Cell Culture Collagen Matrix can be fixed and stained using standard immunofluorescence protocols. The presence of the collagen matrix has little impact on the background fluorescence of the culture, if an appropriate blocking solution is used. The resulting images were defined enough to observe microtubules and actin fibers within the cells in the RAFT<sup>™</sup> 3D Culture. Image quality can be further enhanced by using simple types of image deconvolution software.

In conclusion, with its easy-to-follow protocols, the RAFT<sup>™</sup> System allows researchers to set up biologically relevant 3D cell cultures quickly and reproducibly. Many 2D cell analysis methods can be easily applied to RAFT<sup>™</sup> Cultures, often requiring no, or only minor modifications of existing protocols. This empowers researchers to generate more biologically meaningful data from their cell culture studies in multiple areas of basic research and drug discovery.

### References

1. Pampaloni, F.; Reynaud, E.G.; Stelzer, E.H.K. The third dimension bridges the gap between cell culture and live tissue. *Nat Rev Mol Cell Biol.* 2007, 8, 839–845.

### Clonetics™ Conditionally Immortalized Cells

#### Primary-Like Cells with Cell Line Proliferative Capacity

Cell lines are a common screening model because they are easily bulked up to large, homogenous quantities. They often, however, lack the relevant phenotype of a normal cell. To address this shortcoming, Lonza research solutions developed Clonetics<sup>™</sup> Conditionally Immortalized Cells (CCIC). CCIC are primary cells immortalized with hTERT or ts SV40 L tag to produce a biologically relevant screening model. These cell lines are supplied under license for annual usage. For a complete list of cell types available please see the ordering section page 24.

# We Offer the Following Cell Lines in Our CCIC Portfolio:

- Human Brain Microvascular Endothelial Cells
- Human Preadipocytes
- Human Skeletal Muscle Cells
- Human Dermal Fibroblasts
- Human Coronary Artery Smooth Muscle cells (CASMC)
- Human Blood (BEC) and Lymphatic (LEC) Microvascular Endothelial Cells
- Human Adult Dermal Keratinocytes

### Cells on Demand<sup>™</sup> Services

The advancement of assay technologies has enabled the use of live cells in over 50% of high throughput screening. To meet this growing need, Lonza research solutions has leveraged its decades of cell culture and transfection experience to provide high quality cell products and services.




Figure 1. Podocytes at P4, 10k aSMA overlay (20x)

#### Cells on Demand<sup>™</sup> Transfection Services

Access Lonza's transfection expertise to achieve high transfection efficiencies and viabilities in almost every cell. Benefits include:

- Receive validated stable clones quickly
- Stress-free optimization of Nucleofection<sup>™</sup> Protocols for your cell type of interest

#### Cells on Demand<sup>™</sup> Cell Culture Services

Avoid delays in obtaining vital cell cultures. Just select the cell types and format and our cell culture experts will do the rest.

- Easily move to primary cells with our primary cell expansion service
- Avoid the aggravation of tissue acquisition, failed isolations, and low yields with our primary cell isolation service
- We can establish RAFT<sup>™</sup> 3D Cell Culture Systems tailored to your needs within 96-well or 24-well formats

### **Classical and Specialty Media**

The BioWhittaker<sup>™</sup> Brand provides over 16 high quality media products that fit a variety of cancer applications. Our highly referenced media portfolio contains a variety of liquid and powder formulations that have been supporting therapeutic and research needs for over 20 years. The BioWhittaker<sup>™</sup> Brand includes classical media, reagent, or regulatory friendly specialty media and is manufactured in accordance with cGMP regulations.

🕮 www.lonza.com/culturemedia

# Diabetes-related Differential Gene Expression in Primary Human Adipose-derived Stem Cells and Aortic Endothelial Cells

By Rochelle Myers<sup>1</sup>, Lubna Hussain<sup>1</sup> and Ludger Altrogge<sup>2</sup> <sup>1</sup>Lonza Walkersville, Inc., Walkersville, MD, USA; <sup>2</sup>Lonza Cologne GmbH, Koeln, Germany

### Introduction

With the prevalence of diabetes growing worldwide, the availability of primary human cells from diabetic donors is critical to increase research and knowledge about the disease at a cellular level. In this study, we sought to identify genes differentially regulated in diabetic type 1 and type 2 adipose-derived stem cells (ADSCs) and human aortic endothelial cells (HAECs). ADSCs are isolated from adipose tissue that can selfrenew and are multipotent, immunoprivileged, and immunosuppressive. HAECs are endothelial cells that line macro blood vessels and play important roles in atherosclerosis, inflammation, barrier function, and angiogenesis. The primary cells are isolated from normal and diabetic type 1 and type 2 diagnosed human donors in accordance with all informed consent rules and regulations. The cells were cultured for several passages in optimized media. Gene expression analysis was performed using the Human Insulin Signaling 96 StellARray™ qPCR Array for ADSCs and the Human Endothelial Cell 96 StellARray™ qPCR Array for HAECs available from Bar Harbor Biotechnology. This article summarizes a study comparing normal and diabetic type 1 and type 2 ADSCs and HAECs to explore differences in gene expression among the donor samples.

### **Materials and Methods**

In this study, we grew primary aortic endothelial and adipose-derived stem cells from normal, diabetic type 1 and diabetic type 2 tissues in standard submerged culture (see Table 1) to assess gene expression changes associated with diabetic diseased states.

|          | HAEC Aortic<br>EC—Normal | HAEC<br>Aortic EC—<br>Diabetes<br>Type 1 | HAEC<br>Aortic EC–<br>Diabetes<br>Type 2 | Adipose-<br>derived<br>Stem<br>Cells–<br>Normal | Adipose-<br>derived<br>Stem<br>Cells-<br>Diabetes<br>Type 1 | Adipose-<br>derived<br>Stem<br>Cells-<br>Diabetes<br>Type 2 |
|----------|--------------------------|--|--|---|---|---|
| Cat. No. | CC-2535                  | CC-2919                                  | CC-2920                                  | PT-5006   | PT-5007   | PT-5008   |
| Lot No.  | 0000227953               | 0000239326                               | 0000235247                               | 7F4089  | 1F4104  | 1F4103  |
| Age      | 49 Years                 | 29 Years                                 | 53 Years                                 | 47 Years  | 62 Years  | 83 Years  |
| Sex      | Male                     | Female                                   | Male                                     | Female  | Female  | Female  |
| Race     | Asian                    | Caucasian                                | Caucasian                                | Unknown   | Caucasian   | Caucasian   |

Table 1. Donor characteristics of primary cells used.

#### **Cell Isolation**

Endothelial cells were isolated from normal and diabetic aortae. Isolated cells were expanded in standard submerged culture in EGM<sup>™</sup> 2 Growth Medium (Lonza, cat. no. CC-3162) and then cryopreserved after the third passage. Adipose-derived stem cells from normal and diabetic donors were isolated and cryopreserved at the first passage in ADSC Growth Medium BulletKit<sup>™</sup> (Lonza, cat. no. PT-4505). The vials were stored in liquid nitrogen until further use.

#### Cell Harvesting and Cell Lysis

Each lot of normal and diabetic endothelial cells was thawed and plated at a density of 5,000 cells/cm<sup>2</sup> in EGM<sup>™</sup> 2 Growth Medium (Lonza, cat. no. CC-3162). Each lot of normal and diabetic adipose-derived stem cells was thawed and plated at a density of 5,000 cells/cm<sup>2</sup> in ADSC Growth Medium (Lonza, cat. no. PT-4505). Growth media were changed after 24 hours and the cells were subcultured through multiple passages. At P7, cells were pelleted and cell lysates were obtained using the QlAshredder<sup>™</sup> column (Qiagen, cat. no. 79654).

#### qPCR Experimental Design

To generate data with biologically relevant variance, three replicate samples were independently assayed for each cell type.

#### **RNA Isolation and cDNA Synthesis**

Each cell lysate was transferred to the Qiagen RNeasy® Mini Kit (cat. no. 74104) and RNA was extracted. cDNA was synthesized with 2 µg of RNA per sample using SuperScript® II Reverse Transcriptase and dNTP mix (Life Technologies, cat. no. 18064-014 and 10297-018, respectively). For primers, random decamers and oligo dT primers (Life Technologies, Inc., cat. no. AM5722G and 18418-012) were used. cDNA synthesis reactions were performed according to the specifications of the supplier (see Table 2).

| For Each qPCR Plate, a Reaction Mix was Prepared in the Following Manner             |  |  |
|--|--|--|
| 2x SYBR® Green Master Mix (Life Technologies: Fast SYBR® Green Master Mix)           |  |  |
| H <sub>2</sub> 0   |  |  |
| cDNA template: 40 $\mu$ L cDNA synthesis reaction mix + 310 $\mu$ L H <sub>2</sub> 0 |  |  |

Table 2. Real-time qPCR.

20 µL of the reaction mix was distributed into Human Insulin Signaling 96 StellARray<sup>™</sup> qPCR Array Plate for ADSCs and Human Endothelial Cell 96 StellARray<sup>™</sup> qPCR Array Plate for HAECs. The master mixes contained AmpliTaq<sup>®</sup> Fast DNA Polymerase (Life Technologies, Inc.), designed to allow instant hot start. Arrays were run on the BioRad CFX 96 using a standard qPCR program. Post-run data collection involved the setting of a common threshold (Ct) across all arrays within an experiment, exportation and collation of the Ct values, and analysis via GPR.


### **Results and Discussion**

The Human Insulin Signaling 96 StellARray™ qPCR Array was used to analyze the human adipose-derived stem cell samples. This array was designed with genes to measure the effects of insulin signaling associated with processes like glycogen synthesis, glycolysis, and fatty acid synthesis. The Human Endothelial Cell 96 StellARray™ qPCR Array was used to analyze the human aortic endothelial cell samples. This array was designed to measure genes associated with differentiation, development, and tissue remodeling of endothelium. In each cell type, statistically relevant differences in gene expression were detected in the diabetic cells compared to the normal cells. Genes with P-values of <0.05 or better are reported. Out of the 94 genes on the insulin array, the expression of 18 genes changed by +25.7 to -3.3 fold for ADSC type 1 diabetes and 10 genes changed by +24 to -7.7 fold for type 2 diabetes (as compared to normal cells). Out of the 94 genes on the endothelial array, the expression of 16 genes changed by +17 to -8.7 fold for HAEC type 1 diabetes and 8 genes changed by +52557 to -54 fold for type 2 diabetes (as compared to normal cells). While this article is not meant to be a comprehensive analysis of the genes and their functions in diabetes, we will highlight several genes and their functions.


#### ADSC: Adipose-derived Stem Cells

Among the ADSC diabetic type 1 and type 2 cells (Figures 1 and 2), the two most upregulated genes (as compared to the normal) for both were INS (insulin) and G6PC2 (glucose-6-phosphatase, catalytic, 2). G6PC2 encodes an enzyme that belongs to the G6PC family. These enzymes are part of a larger unit that catalyzes the hydrolysis of G6PC, which releases glucose into the bloodstream. The enzyme family member specific to G6PC2 is found in pancreatic islets and is a main target of cell-mediated autoimmunity in diabetes<sup>1</sup>.

In the ADSC type 2 diabetic donors (Figure 2), PPARGC1A was downregulated 7 fold as compared to the normal donors. PPARGC1A encodes for a transcriptional coactivator protein that regulates genes involved in energy metabolism<sup>2</sup>.









#### HAEC: Human Aortic Endothelial Cells

In the HAEC diabetic type 1 and type 2 cells (Figures 3 and 4), a common upregulated gene was SELE (14 fold in type 1 and 33.5 fold in type 2). E-selectin (SELE) is expressed by endothelial cells to recruit leukocytes during the inflammatory response, and increased levels of E-selectin are associated with type 2 diabetes. One study suggested that in high glucose conditions, macrophage stimulation of E-selectin may play a role in atherogenesis, and suggested this as a mechanism as to why arterial disease is accelerated in diabetes<sup>3</sup>.

Hepatocyte growth factor (HGF) was downregulated in both type 1 (8.8 fold) and type 2 (54 fold) diabetic cells (Figures 3 and 4) when compared to the normal donor cells. Increasing the concentration of HGF has been shown to induce therapeutic angiogenesis in high glucose environments in rats and to lessen apoptosis in human endothelial cells<sup>4,5</sup>. Injury to aortic endothelial cells has been suggested to be a trigger of the progression of atherosclerosis in diabetic patients<sup>5</sup>.

In the HAEC type 2 diabetic samples, AGER (advanced glycosylation end product-specific receptor) was downregulated 7 fold as compared to the normal donor samples. The receptor encoded by this gene interacts with molecules implicated in homeostasis, inflammation, and diabetes<sup>6</sup>.

### Summary

Data generated from this study shows up- and downregulation of genes in ADSC and HAEC cells from diabetic type 1 and type 2 donors as compared to normal donors using the StellARray<sup>™</sup> qPCR Arrays. This data has indicated several differences in gene expression between the normal and diabetic cells from both cell types and is consistent with other published literature. The utility of primary cells has further strengthened the biological relevance of data generated as it relates more closely to the *in vivo* model. Results from this study encourage further exploration as to how diseases such as diabetes affect systems in the body and cause differences in gene expression and gene regulation pathways.

Lonza offers a variety of primary cells from diabetic type 1 and type 2 donors. In addition, Lonza introduced, through our Cells on Demand<sup>™</sup> service, fresh pancreatic islets from normal and diabetic donors for research use. Type 1 diabetes is characterized by the immune system destroying insulin-secreting beta cells of the pancreas. Islet-transplantation replenishes the beta cell supply, rendering better regulation of insulin levels. Additional information about any of Lonza's cell offerings can be obtained from Lonza's Scientific Support Team.





Figure 3. Genes up-or downregulated in HAEC diabetes type 1 sample vs. normal cells.





### References

- 1. Pubmed GENE ID 57818 description, (10Nov2012).
- 2. Pubmed GENE ID 10891 description, (10Nov2012).
- 3. Chen T, et al. *J Biol Chem.* 2011. 286(29):25564–73.
- 4. Taniyama Y, et al. *Circulation*. 2001. 104(19):2344–50.
- 5. Nakagami H, et al. *Diabetes*. 2002. 51(8):2604–2611.
- 6. Pubmed GENE ID 177 description, (10Nov2012).

### Cell Analysis Tools for Metabolic Research

Utilize Lonza's research tools for every step of your workflow. Lonza provides everything you need for biologically relevant results – from culture media, sample preparation, all the way through protein confirmation.

### AdipoLyze™ Lipolysis Detection Assay

The AdipoLyze<sup>™</sup> Lipolysis Detection Assay is a fast, sensitive, fluorescent *in vitro* assay used for detecting small quantities of glycerol in cells undergoing lipolysis.

### AdipoRed<sup>™</sup> Assay Reagent

The AdipoRed<sup>™</sup> Assay Reagent is designed for assessing the effect of compounds on the differentiation of preadipocytes or on lipid utilization in mature adipocytes. This objective, high-throughput, homogeneous fluorescence-based assay quantifies the accumulation of intracellular triglycerides and provides significant advantages to drug discovery efforts.

### ToxiLight<sup>™</sup> Kit

Check a compound's cytotoxic effects non-destructively by measuring adenylate kinase (AK) leakage from damaged cells.

### ViaLight<sup>™</sup> Plus Kit

Measure cell viability using bioluminescent detection of cellular ATP as a measure of viability; the most accurate, effective, and direct way of determining the number of living cells in culture.

### MycoAlert™ Mycoplasma Detection Assay

The MycoAlert<sup>™</sup> Assay Kit is a selective biochemical test that exploits the activity of specific mycoplasmal enzymes which are found in all 6 of the main mycoplasma cell culture contaminants and the vast majority of 180 species of mycoplasma.

"I can't find reliable assay tools to study drug effects on protein expression, cell proliferation, or cytotoxicity."

SOLUTION: Choose from our variety of assay tools, including readyto-use protein gels, and bioassay kits to measure cell proliferation and cytotoxicity.



### OsteoAssay<sup>™</sup> Human Bone Plate

The OsteoAssay<sup>™</sup> Plate provides a thin layer of adherent real human bone for the culture of primary human or non-human osteoclasts, osteoclast precursors, or immortalized cell lines. Cells can be stained with standard cytochemical or immunofluorescent techniques. Assays of bone resorption and osteoclast precursor differentiation can be performed easily by sampling the cell culture supernatant.

### OsteoImage<sup>™</sup> Mineralization Assay

The OsteoImage<sup>™</sup> Mineralization Assay is a rapid, fluorescent *in vitro* assay for assessing bone cell mineralization. The OsteoImage<sup>™</sup> Assay can quantitate *in vitro* mineralization by osteogenic stem cells, primary osteoblasts, and osteoblast-like cell lines. It is based on specific binding of the fluorescent OsteoImage<sup>™</sup> Staining Reagent to the hydroxyapatite portion of bone-like nodules deposited by cells. Unlike typical histochemical methods such as von Kossa and Alizarin red, neither of which is hydroxyapatite specific, the OsteoImage<sup>™</sup> Assay eliminates multiple steps or tedious extraction steps.

### OsteoLyse<sup>™</sup> Assay Kit

The OsteoLyse<sup>™</sup> Assay Kit provides an easy to use protocol for quantitatively measuring *in vitro* osteoclast-mediated bone resorption in a highthroughput format. Osteoclasts can be seeded onto the OsteoLyse<sup>™</sup> Plate using traditional cell culture protocols. The assay directly measures the release of Europium-labeled collagen fragments into the osteoclast cell culture supernatant via time resolved fluorescence, indicating their resorption activity levels.

# Cell Analysis Tools – Live Cell Monitoring

### CytoSMART<sup>™</sup> System

#### Your Cell Culture is Just One Click Away

Monitor your cell culture anytime using our new CytoSMART<sup>™</sup> System – your personal live cell monitoring device. The System consists of a mini-microscope and the CytoSMART<sup>™</sup> Device that is linked to an accompanying tablet outside the incubator. Via this tablet you start your CytoSMART<sup>™</sup> Projects and capture the images of your cell culture in defined intervals. All images are transmitted to the CytoSMART<sup>™</sup> Connect Cloud via wireless transmission (WiFi), meaning you can monitor your cell culture remotely and in real-time with any browsercapable device, be it your smartphone, tablet or PC.

#### The Smarter Way for Precious Cell Cultures

With the CytoSMART<sup>™</sup> System your cells can remain in their defined conditions in the incubator while you monitor the cell culture online.

- Easy documentation and video-taping of your cell culture
- Remote monitoring of cultures grown under defined conditions (e.g. hypoxia)
- Cell culture standardization through operator independent determination of confluency with automatic alerts for cell culture functionality
- Easy and immediate download of cell culture images or videos from CytoSMART<sup>™</sup> Connect Cloud

www.lonza.com/cytosmart



Figure 1. Image of human skeletal muscle cells (SkMC, CC-2561) cultured in SkGM using the CytoSMART<sup>™</sup> Lux 10X System. Please refer to our website to view the video of a SkMC culture recorded with the CytoSMART<sup>™</sup> System.

### Molecular Biology Products

#### **Nucleic Acid Electrophoresis**

- General and Speciality agarose
- Latitude<sup>™</sup> and Reliant<sup>™</sup> Pre-cast gels
- DNA and gel stains
- AccuGene<sup>™</sup> Buffers
- FlashGel<sup>™</sup> System

#### **Protein Electrophoresis**

- PAGEr™ EX and PAGEr™ Gold Gels
- ProSieve Buffers
- Stains and Reagents
- ProSieve™ EX Reagents

Lonza's molecular biology products offer basic aspects of cancer research. Speed up your results from PCR analysis, RNA integrity analysis, to fragment isolation for cloning. Lonza's FlashGel™ System can get you there in minutes. For protein analysis and western blotting Lonza's PAGEr™ EX Gels and ProSieve™ EX Reagents help speed your research from hours to minutes.

## **Custom Research Solutions**

If you're looking for customized research solutions or expert support services, just ask your local Lonza representative. They can put you in touch with experts who have decades of experience in cell isolation, transfection, and testing services.

### **Custom Cell and Screening Services**

You can order virtually any human or animal cell through our vast tissue network. Lonza's isolation experts can provide you with:

- A broad range of cells, packaged to your specifications
- Customized treatments, such as cell pelleting, personalized media, and specific treatment prior to cryopreservation

### Scientific Support

For advice or information on any Lonza product, just contact our scientific support team. They offer:

- More than 50 years of combined troubleshooting experience
- Educational webinars
- Real disease research application data
- You can find contact details for your regional support team on the back of this brochure.

# Ordering Information

| Cat. No.                    | Description  | Size              |
|-----------------------------|--|-------------------|
| RAFT <sup>™</sup> 3D Cell 0 | Culture System   |                   |
| 016-1R10                    | RAFT™ 96-well Bundle Kit, contains (016-0R94 & 016-0R92)   | Kit               |
| 016-1R24                    |  | Kit               |
| 016-1R25                    |  | Kit               |
| 016-1R16                    |  | Kit               |
| 016-1R32                    | RAFT <sup>™</sup> Absorbers, for 24-well Plate   | 48                |
| 016-1R33                    |  | 48 inserts        |
| 016-0R92                    |  | Kit               |
| 016-0R94                    | RAFT™ Reagent Kit, Reagent Kit for 3D Cell Cultures  | Kit               |
| CytoSMART <sup>™</sup> Sy   | ustem  |                   |
| AACS-1001                   | CytoSMART™ LUX 10X System, contains CytoSMART™ Lux 10X Device, accompanying tablet<br>and two year free CytoSMART™ Connect Cloud Service | -                 |
| AWCS-1001                   | CytoSMART™ Connect Cloud One Year Renewal, Automatic renewal of CytoSMART™ Connect Cloud Service for one year                            | _                 |
| AAK-2003                    | <br>CytoSMART™ Stage Attachment, allows viewing of T162 flasks   |                   |
| Cardiovascular              |  |                   |
|                             |  |                   |
| CC-2535                     | HAEC – Human Aortic Endothelial Cells in EGM™ 2, cryopreserved   | ≥500 000 cells    |
| CC-2920                     | D-HAEC – Human Aortic endo, Diabetes Type II in EGM™ 2, cryopreserved  | ≥500 000 cells    |
| CC-2919                     | D-HAEC – Human Aortic endo, Diabetes Type I in EGM™ 2, cryopreserved   | ≥500 000 cells    |
| CC-2585                     | HCAEC – Human Coronary Artery Endothelial Cells in EGM™ 2MV, cryopreserved   | ≥500 000 cells    |
| CC-2922                     | D-HCAEC – Human Coronary Artery Endothelial Cells, Diabetes Type II in EGM™ 2MV, cryopreserved   | ≥500 000 cells    |
| CC-2921                     | D-HCAEC – Human Coronary Artery Endothelial Cells, Diabetes Type I in EGM™ 2MV, cryopreserved  | ≥500 000 cells    |
| CC-2530                     | HPAEC – Human Pulmonary Artery Endothelial Cells in EGM <sup>™</sup> 2, cryopreserved  | ≥500 000 cells    |
| CC-2924                     | D-HPAEC – Human Pulmonary Artery Endothelial Cells, Diabetes Type II in EGM™ 2, cryopreserved  | ≥500 000 cells    |
| CC-2923                     | D-HPAEC – Human Pulmonary Artery Endothelial Cells, Diabetes Type I in EGM™ 2, cryopreserved   | ≥500 000 cells    |
| CC-7030                     | HMVEC-C – Human Cardiac Microvascular Endothelial Cells in EGM™ 2MV, cryopreserved   | ≥500 000 cells    |
| CC-2928                     | D-HMVEC – Human Cardiac Microvascular Endothelial Cells, Diabetes Type II in EGM™ 2MV, cryopreserved                                     | ≥500 000 cells    |
| CC-2927                     | D-HMVEC – Human Cardiac Microvascular Endothelial Cells, Diabetes Type I in EGM™ 2MV, cryopreserved                                      | ≥500 000 cells    |
| CC-2543                     | HMVEC-dAd — Human Adult Dermal Microvascular Endothelial Cells in EGM™ 2MV, cryopreserved  | ≥500 000 cells    |
| CC-2930                     | D-HMVEC – Human Dermal Microvascular Endothelial Cells, Diabetes Type II in EGM™ 2MV, cryopreserved                                      | ≥500 000 cells    |
| CC-2929                     | D-HMVEC – Human Dermal Microvascular Endothelial Cells, Diabetes Type I in EGM™ 2MV, cryopreserved                                       | ≥500 000 cells    |
| CC-2545                     | HIAEC – Human Iliac Artery Endothelial Cells in EGM™ 2MV, cryopreserved  | ≥500 000 cells    |
| C2519A                      | HUVEC – Human Umbilical Vein Endothelial Cells, pooled, in EGM™ 2, cryopreserved   | ≥500 000 cells    |
| C2517A                      | HUVEC – Human Umbilical Vein Endothelial Cells, single donor, in EGM™ 2, cryopreserved   | ≥500 000 cells    |
| 00191027                    | HUVEC-XL™ – Human Umbilical Vein Endothelial Cells, expanded, cryopreserved  | ≥10 million cells |
| CC-2527                     | HMVEC-L – Human Lung Microvascular Endothelial Cells in EGM™ 2MV, cryopreserved  | ≥500 000 cells    |
| CC-2581                     | PASMC – Human Pulmonary Artery Smooth Muscle Cells, in SmGM™ 2, cryopreserved  | ≥500 000 cells    |
| CC-2913                     | D-PASMC – Human Pulmonary Artery Smooth Muscle Cells, Diabetes Type II in SmGM™ 2, cryopreserved   | ≥500 000 cells    |
| CC-2915                     | D-PASMC – Human Pulmonary Artery Smooth Muscle Cells, Diabetes Type I in SmGM™ 2, cryopreserved  | ≥500 000 cells    |
| CC-2571                     | AoSMC – Human Aortic Smooth Muscle Cells, in SmGM™ 2, cryopreserved  | ≥500 000 cells    |
| CC-2916                     | D-AoSMC — Human Aortic Smooth Muscle Cells, Diabetes Type II in SmGM™ 2, cryopreserved   | ≥500 000 cells    |
| CC-2914                     | D-AoSMC — Human Aortic Smooth Muscle Cells, Diabetes Type I in SmGM™ 2, cryopreserved  | ≥500 000 cells    |
| CC-2583                     | CASMC – Human Coronary Artery Smooth Muscle Cells, in SmGM™ 2, cryopreserved   | ≥500 000 cells    |

| Cat. No.        | Description   | Size             |
|-----------------|---|------------------|
| Cardiovascula   | ar Cells (Continued)  |                  |
| CC-2918         | D-CASMC – Human Coronary Artery Smooth Muscle Cells, Diabetes Type II in SmGM™ 2, cryopreserved | ≥500 000 cells   |
| CC-2917         | D-CASMC – Human Coronary Artery Smooth Muscle Cells, Diabetes Type I in SmGM™ 2, cryopreserved  | ≥500 000 cells   |
| CC-7014         | AoAF – Human Aortic Adventitial Fibroblasts in SCGM™, cryopreserved                             | ≥500 000 cells   |
| CC-2579         | UASMC – Human Umbilical Artery Smooth Muscle Cells, in SmGM™ 2, cryopreserved                   | ≥500 000 cells   |
| Skeletal Musc   | le Cells  |                  |
| CC-2580         | HSMM – Human Skeletal Muscle Myoblasts, in SkGM™ 2, cryopreserved                               | ≥500 000 cells   |
| CC-2901         | D-HSMM – Human Skeletal Muscle Myoblasts, Diabetes Type II in SkGM™ 2, cryopreserved            | ≥500 000 cells   |
| CC-2900         | D-HSMM — Human Skeletal Muscle Myoblasts, Diabetes Type I in SkGM™ 2, cryopreserved             | ≥500 000 cells   |
| Intestinal Cell | S   |                  |
| CC-2902         | H-InMyoFib – Human Intestinal Myofibroblasts in SmGM™, cryopreserved                            | ≥500 000 cells   |
| CC-2931         | H-InEpC – Human Intestinal Epithelial Cells in SmGM™, cryopreserved                             | ≥800 000 cells   |
| Renal Cells     |   |                  |
| CC-2553         | RPTEC – Human Renal Proximal Tubule Cells in REGM™, cryopreserved                               | ≥500 000 cells   |
| CC-2925         | D-RPTEC – Human Renal Proximal Tubule Cells, Diabetes Type II in REGM™, cryopreserved           | ≥500 000 cells   |
| CC-2554         | HRCE – Human Renal Cortical Epithelial Cells in REGM™, cryopreserved                            | ≥500 000 cells   |
| CC-2556         | HRE – Human Renal Epithelial Cells in REGM™, cryopreserved                                      | ≥500 000 cells   |
| Dermal Cells    |   |                  |
| 00192627        | HRE – Human Renal Epithelial Cells in REGM, in KGM™ Gold, cryopreserved                         | ≥500 000 cells   |
| CC-2926         | D-HEK – Human Adult Epidermal Keratinocytes, Diabetes Type II in KGM™ Gold, cryopreserved       | ≥500 000 cells   |
| Adipose Cells   |   |                  |
| PT-5005         | Preadipocytes, Human Visceral Cells in PGM™ 2, cryopreserved                                    | ≥1 million cells |
| PT-5024         | Preadipocytes, Human Visceral Cells, Diabetes Type II in PGM™ 2, cryopreserved                  | ≥1 million cells |
| PT-5023         | Preadipocytes, Human Visceral Cells, Diabetes Type I in PGM™ 2, cryopreserved                   | ≥1 million cells |
| PT-5020         | Preadipocytes, Human Subcutaneous Cells in PGM™ 2, cryopreserved                                | ≥1 million cells |
| PT-5001         | Preadipocytes, Human Subcutaneous Cells in PGM™ 2, cryopreserved                                | ≥4 million cells |
| PT-5022         | Preadipocytes, Human Subcutaneous Cells, Diabetes Type II in PGM™ 2, cryopreserved              | ≥1 million cells |
| PT-5021         | Preadipocytes, Human Subcutaneous Cells Diabetes Type I in PGM™ 2, cryopreserved                | ≥1 million cells |
| PT-5006         | Adipose-Derived Human Stem Cells  | ≥1 million cells |
| PT-5008         | D-ADSC – Adipose-Derived Human Stem Cells, Diabetes Type II                                     | ≥1 million cells |
| PT-5007         | D-ADSC – Adipose-Derived Human Stem Cells, Diabetes Type I                                      | ≥1 million cells |

Metabolic Research – Related Media on next page.

# Ordering Information

| Cat. No.                        | Description   | Size  |
|---------------------------------|---|---|
| Immortalized Cells              | for Metabolic Research                                    |   |
| XM13A1                          | Skeletal Muscle Cells                                     | _   |
| XM15B1                          | Skeletal Muscle Cells                                     |   |
| XA15A1                          | Adipocytes  |   |
| XF05C1                          | Human Dermal Fibroblasts                                  | _   |
| XS12C1                          | Human Coronary Artery Smooth Muscle Cells                 | _   |
| XSEL6C1                         | Dermal Microvascular LEC                                  |   |
| XSEB113C1                       | Dermal Microvascular BEC                                  |   |
| XSKA1B1                         | Adult Keratinocytes                                       |   |
| 00194607                        | Human Brain Microvascular Endothelial Cells               |   |
| Metabolic Research              | Media   |   |
| CC-3162                         | EGM™ 2 – Endothelial Cell Growth Medium-2 BulletKit™      | Kit   |
| CC-3202                         |   | Kit   |
| 00192060                        | <br>KGM™ Gold – Keratinocyte Growth Medium BulletKit™     | Kit   |
| CC-3190                         | REGM™ – Renal Epithelial Cell Growth Medium BulletKit™    | Kit   |
| CC-3245                         | SkGM™ 2 – Skeletal Muscle Cell Growth Medium-2 BulletKit™ | Kit   |
| CC-3182                         | SmGM™ 2 – Smooth Muscle Growth Medium-2 BulletKit™        | Kit   |
| PT-8002                         | <br>PGM™ 2 – Preadipocyte Growth Medium-2 BulletKit™      | Kit   |
| PT-4505                         | ADSC Growth Medium BulletKit™                             | Kit   |
| CC-5034                         |   | 100 mL each   |
| Metabolic Research              | -Related Assays   |   |
| 00193339                        | AdipoLyze™ Lipolysis Detection Assay                      | 1 × 96-wells  |
| PT-7009                         | AdipoRed™ Adipogenesis Assay Reagent                      | 5 × 4.0 mL  |
| Nucleofector <sup>™</sup> Devic | ces   |   |
| AAB-1001                        | Nucleofector™ 2b Device                                   | _   |
| AAF-1001B                       | 4D-Nucleofector™ Core Unit                                |   |
| AAF-1001X                       | 4D-Nucleofector™ X Unit                                   | _   |
| AAM-1001S                       | 96-well Shuttle™ Device                                   |   |
| Kits for 4D-Nucleof             | ector™  |   |
| V4XP-1012                       | P1 Primary Cell Kit                                       | 12 rxn (100 µl Nucleocuvette™)                      |
| V4XP-1024                       |   | 24 rxn (100 µl Nucleocuvette <sup>**</sup> )        |
| V4XP-1032                       |   | 32 rxn (20 µl Nucleocuvette <sup>™</sup> ; 16-well) |
| V4XP-2012                       | P2 Primary Cell Kit                                       | 12 rxn (100 µl Nucleocuvette™)                      |
| V4XP-2024                       |   | 24 rxn (100 μl Nucleocuvette <sup>™</sup> )         |
| V4XP-2032                       |   | 32 rxn (20 µl Nucleocuvette <sup>™</sup> ; 16-well) |
| V4XP-3012                       | P3 Primary Cell Kit                                       | 12 rxn (100 µl Nucleocuvette™)                      |
| V4XP-3024                       |   | 24 rxn (100 μl Nucleocuvette <sup>™</sup> )         |
| V4XP-3032                       |   | 32 rxn (20 µl Nucleocuvette <sup>™</sup> ; 16-well) |
| V4XP-4012                       | P4 Primary Cell Kit                                       | 12 rxn (100 µl Nucleocuvette™)                      |
| V4XP-4024                       |   | 24 rxn (100 µl Nucleocuvette™)                      |
|                                 |   |   |

| Cat. No.         | Description                                      | Size   |
|------------------|--|--|
| Kits for 4D-Nuc  | leofector™ (Continued)                           |  |
| V4XP-5012        | P5 Primary Cell Kit                              | 12 rxn (100 µl Nucleocuvette™)                                     |
| V4XP-5024        |  | 24 rxn (100 µl Nucleocuvette™)                                     |
| V4XP-5032        |  | 32 rxn (20 μl Nucleocuvette™; 16-well)                             |
| V4XP-9096        | Primary Cell Optimization Kit                    | 96 rxn (20 µl Nucleocuvette™; 16-well)                             |
| V4XC-1012        | SE Cell Line Kit                                 | 12 rxn (100 µl Nucleocuvette™)                                     |
| V4XC-1024        |  | 24 rxn (100 µl Nucleocuvette™)                                     |
| V4XC-1032        |  | 32 rxn (20 μl Nucleocuvette™; 16-well)                             |
| V4XC-2012        | SF Cell Line Kit                                 | 12 rxn (100 µl Nucleocuvette™)                                     |
| V4XC-2024        |  | 24 rxn (100 µl Nucleocuvette™)                                     |
| V4XC-2032        |  | 32 rxn (20 µl Nucleocuvette™; 16-well)                             |
| V4XC-3012        | SG Cell Line Kit                                 | 12 rxn (100 µl Nucleocuvette™)                                     |
| V4XC-3024        |  | 24 rxn (100 µl Nucleocuvette™)                                     |
| V4XC-3032        |  | 32 rxn (20 µl Nucleocuvette™; 16-well)                             |
| V4XC-9064        | Cell Line Optimization Kit                       | 64 rxn (20 µl Nucleocuvette™; 16-well)                             |
| Kits for 96-well | Shuttle <sup>™</sup> Device                      |  |
| V4SP-1096        | P1 Primary Cell Kit                              | 96 rxn (20 µl Nucleocuvette™; 96-well)                             |
| V4SP-1960        |  | 960 rxn (20 μl Nucleocuvette™; 96-well)                            |
| V4SP-2096        | P2 Primary Cell Kit                              | 96 rxn (20 μl Nucleocu∨ette™; 96-well)                             |
| V4SP-2960        |  | 960 rxn (20 µl Nucleocuvette™; 96-well)                            |
| V4SP-3096        | P3 Primary Cell Kit                              | 96 rxn (20 μl Nucleocu∨ette™; 96-well)                             |
| V4SP-3960        |  | 960 rxn (20 µl Nucleocuvette™; 96-well)                            |
| V4SP-4096        | P4 Primary Cell Kit                              | 96 rxn (20 μl Nucleocu∨ette™; 96-well)                             |
| V4SP-4960        |  | 960 rxn (20 µl Nucleocuvette™; 96-well)                            |
| V4SP-5096        | P5 Primary Cell Kit                              | 96 rxn (20 μl Nucleocuvette™; 96-well)                             |
| V4SP-5960        |  | 960 rxn (20 µl Nucleocuvette™; 96-well)                            |
| V4SP-9096        | Primary Cell Optimization Kit                    | 96 rxn (20 μl Nucleocuvette™; 96-well)                             |
| V4SC-1096        | SE Cell Line Kit                                 | 96 rxn (20 μl Nucleocuvette™; 96-well)                             |
| V4SC-1960        |  | 960 rxn (20 µl Nucleocuvette™; 96-well)                            |
| V4SC-2096        | SF Cell Line Kit                                 | 96 rxn (20 μl Nucleocuvette™; 96-well)                             |
| V4SC-2960        |  | 960 rxn (20 μl Nucleocuvette™; 96-well)                            |
| V4SC-3096        | SG Cell Line Kit                                 | 96 rxn (20 µl Nucleocuvette™; 96-well)                             |
| V4SC-3960        |  | 960 rxn (20 μl Nucleocuvette™; 96-well)                            |
| V4SC-9096        | Cell Line Optimization 96-Well-Nucleofector™ Kit | 96 rxn (20 µl Nucleocuvette™; 96-well)                             |
| Kits for Nucleof | ector™ II/2b Device                              |  |
| VAPC-1001        | AoSMC Nucleofector™ Kit                          | 10 rxn (100 μL aluminum cuvette)                                   |
| VPC-1001         |  | 25 rxn (100 µL aluminum cuvette)                                   |
| VVPC-1001        |  | $4 \times 25 \operatorname{rxn} (100 \text{ µL aluminum cuvette})$ |

| VAPC-1001 | AoSMC Nucleofector™ Kit                    | 10 rxn (100 μL aluminum cuvette)     |
|-----------|--|--------------------------------------|
| VPC-1001  |  | 25 rxn (100 μL aluminum cuvette)     |
| VVPC-1001 |  | 4 × 25 rxn (100 μL aluminum cuvette) |
| VAPI-1004 | Basic Smooth Muscle Cell Nucleofector™ Kit | 10 rxn (100 μL aluminum cuvette)     |
| VPI-1004  |  | 25 rxn (100 μL aluminum cuvette)     |
| VVPI-1004 |  | 4 × 25 rxn (100 μL aluminum cuvette) |

🖊 Continued on next page

# Ordering Information

| Cat. No.            | Description                                  | Size  |
|---------------------|--|---|
| Kits for Nucleofect | tor™ II/2b Device (Continued)                |   |
| VAPB-1001           | HCAEC Nucloefector™ Kit                      | 10 rxn (100 μL aluminum cuvette)                                |
| VPB-1001            |  | 25 rxn (100 μL aluminum cuvette)                                |
| /VPB-1001           |  | 4 × 25 rxn (100 μL aluminum cuvette)                            |
| VAPI-1001           | <br>Basic Endothelial Cell Nucleofector™ Kit | 10 rxn (100 μL aluminum cuvette)                                |
| VPI-1001            |  | 25 rxn (100 μL aluminum cuvette)                                |
| /VPI-1001           |  | 4 × 25 rxn (100 μL aluminum cuvette)                            |
| /APB-1002           | –<br>HUVEC Nucleofector™ Kit                 | 10 rxn (100 μL aluminum cuvette)                                |
| /PB-1002            |  | 25 rxn (100 μL aluminum cuvette)                                |
| /VPB-1002           |  | $4 \times 25 \text{ rxn} (100 \ \mu\text{L} aluminum cuvette})$ |
| /APB-1003           |  | 10 rxn (100 μL aluminum cuvette)                                |
| /PB-1003            |  | 25 rxn (100 μL aluminum cuvette)                                |
| /VPB-1003           |  | 4 × 25 rxn (100 μL aluminum cuvette)                            |
| /API-1002           | Basic Fibroblast Nucloefector™ Kit           | 10 rxn (100 μL aluminum cuvette)                                |
| VPI-1002            |  | 25 rxn (100 µL aluminum cuvette)                                |
| VVPI-1002           |  | 4 × 25 rxn (100 μL aluminum cuvette)                            |
| /API-1005           | Basic Epithelial cell Nucleofector™ Kit      | 10 rxn (100 µL aluminum cuvette)                                |
| /PI-1005            |  | 25 rxn (100 μL aluminum cuvette)                                |
| /VPI-1005           |  | $4 \times 25$ rxn (100 µL aluminum cuvette)                     |
| /APD-1002           | Human Keratinocyte Nucleofector™ Kit         | 10 rxn (100 µL aluminum cuvette)                                |
| /PD-1002            |  | 25 rxn (100 µL aluminum cuvette)                                |
| /VPD-1002           |  | $4 \times 25$ rxn (100 µL aluminum cuvette)                     |
| /APE-1001           | Human MSC Nucleofector™ Kit                  | 10 rxn (100 µL aluminum cuvette)                                |
| /PE-1001            |  | 25 rxn (100 µL aluminum cuvette)                                |
| /VPE-1001           |  | $4 \times 25$ rxn (100 µL aluminum cuvette)                     |
| /APL-1004           | Mouse/Rat Hepatocyte Nucleofector™ Kit       | 10 rxn (100 µL aluminum cuvette)                                |
| /PL-1004            |  | 25 rxn (100 µL aluminum cuvette)                                |
| /VPL-1004           |  | $4 \times 25$ rxn (100 µL aluminum cuvette)                     |
| /ACA-1005           | Cell Line L                                  | 10 rxn (100 µL aluminum cuvette)                                |
| /CA-1005            |  | 25 rxn (100 µL aluminum cuvette)                                |
| /VCA-1005           |  | $4 \times 25$ rxn (100 µL aluminum cuvette)                     |
| /ACA-1002           | Cell Line T                                  | 10 rxn (100 µL aluminum cuvette)                                |
| /CA-1002            |  | 25 rxn (100 µL aluminum cuvette)                                |
| /VCA-1002           |  | $4 \times 25$ rxn (100 µL aluminum cuvette)                     |
| /ACA-1003           | Cell Line V                                  | 10 rxn (100 µL aluminum cuvette)                                |
| /CA-1003            |  | 25 rxn (100 μL aluminum cuvette)                                |
| /VCA-1003           |  | 4 × 25 rxn (100 μL aluminum cuvette)                            |
| /ACA-1001           | Cell Line R                                  | 10 rxn (100 µL aluminum cuvette)                                |
| /CA-1001            |  | 25 rxn (100 µL aluminum cuvette)                                |
| /VCA-1001           |  | 4 × 25 rxn (100 µL aluminum cuvette)                            |
| /ACA-1004           | Cell Line C                                  | 10 rxn (100 µL aluminum cuvette)                                |
| VCA-1004            |  | 25 rxn (100 µL aluminum cuvette)                                |
| /VCA-1004           |  | 4 × 25 rxn (100 μL aluminum cuvette)                            |
| /CO-1001N           | Cell Line Optimization Kit                   | 18 reactions (100 µL aluminum cuvette)                          |

| Cat. No.                   | Description               | Size   |  |  |  |
|----------------------------|---------------------------|--|--|--|--|
| FlashGel <sup>™</sup> Syst | tem for RNA               |  |  |  |  |
| 57027                      | FlashGel™ RNA Cassettes   | 1.2% agarose, 12 + 1 single-tier, 9 pk               |  |  |  |
| 57028                      |                           | 1.2% agarose, 16 + 1 double-tier (34-well), 9 pk     |  |  |  |
| 50462                      |                           | 5 × 1 mL, 5X concentration, RNA native sample buffer |  |  |  |
| 50577                      |                           | 50 μg, band sizes: 0.5/1/1.5/3/5/9 kb                |  |  |  |
| 57024                      | FlashGel™ RNA Starter Kit |  |  |  |  |

| PAGEr™ Gels and Accessories        |                    | finitia             | TIMITTIM            | TANANATANANAT       |                     | <b>MARCENT</b>      |                        |
|------------------------------------|--------------------|---------------------|---------------------|---------------------|---------------------|---------------------|------------------------|
| Gel Concentration/Separation Range | Cassette Size (cm) | Cat. No.<br>2D-Well | Cat. No.<br>10-Well | Cat. No.<br>12-Well | Cat. No.<br>16-Well | Cat. No.<br>17-Well | Cat. No.<br>8 + 1 Well |
| 4 – 12% gradient<br>25 – 250 kDa   | 9 × 10<br>10 × 10  | -                   | 58520<br>59520      | 58522<br>59522      | 58524<br>59524      | -                   | -                      |
| 4 – 20% gradient                   | 9 × 10             | _                   | 58511               | 58505               | 58517               | 58545               | 58551                  |
| 5 – 200 kDa                        | 10 × 10            | 59557               | 59511               | 59505               | 59517               | 59545               | 59551                  |
| 8 – 16% gradient                   | 9 × 10             | _                   | 58519               | 58521               | 58523               | 58560               | 58562                  |
| 15 – 200 kDa                       | 10 × 10            | 59564               | 59519               | 59521               | 59523               | 59560               | 59562                  |
| 10 – 20% gradient<br>5 – 150 kDa   | 9 × 10<br>10 × 10  | -                   | 58512<br>59512      | 58506<br>59506      | 58518<br>59518      |                     | -                      |
| 7.5%<br>50 – 200 kDa               | 9 × 10<br>10 × 10  |                     | 58507<br>59507      | 58501<br>59501      | 58513<br>59513      | 58540               |                        |
| 10%                                | 9 × 10             | _                   | 58508               | 58502               | 58514               | 58542               | 58548                  |
| 25 – 200 kDa                       | 10 × 10            | 59554               | 59508               | 59502               | 59514               | 59542               | 59548                  |
| 12%                                | 9 × 10             | _                   | 58509               | 58503               | 58515               | 58543               |                        |
| 20 – 200 kDa                       | 10 × 10            | 59571               | 59509               | 59503               | 59515               | 59543               |                        |
| 15%                                | 9 × 10             | _                   | 58510               | 58504               | 58516               | 58544               | 58550                  |
| 10 – 50 kDa                        | 10 × 10            | 59556               | 59510               | 59504               | 59516               | 59544               | 59550                  |

🜐 www.lonza.com/protein – For PAGEr™ Gel formats and accessories.

### **Contact Information**

#### North America

Customer Service: +1 800 638 8174 (toll free) order.us@lonza.com Scientific Support: +1 800 521 0390 (toll free) scientific.support@lonza.com

#### Europe

Customer Service: +32 87 321 611 order.europe@lonza.com Scientific Support: +32 87 321 611 scientific.support.eu@lonza.com

#### International

Contact your local Lonza distributor Customer Service: +1 301 898 7025 Fax: +1 301 845 8291 scientific.support@lonza.com

#### International Offices

| Australia       | + 61 3 9550 0883           |  |  |  |  |
|-----------------|----------------------------|--|--|--|--|
| Belgium         | + 32 87 321 611            |  |  |  |  |
| Brazil          | + 55 11 2069 8800          |  |  |  |  |
| France          | 0800 91 19 81 (toll free)  |  |  |  |  |
| Germany         | 0800 182 52 87 (toll free) |  |  |  |  |
| India           | +91 22 4342 4000           |  |  |  |  |
| Japan           | + 81 3 6264 0660           |  |  |  |  |
| Luxemburg       | +32 87 321 611             |  |  |  |  |
| Singapore       | + 65 6521 4379             |  |  |  |  |
| The Netherlands | 0800 022 4525 (toll free)  |  |  |  |  |
| United Kingdom  | 0808 234 97 88 (toll free) |  |  |  |  |

Lonza Cologne GmbH – 50829 Cologne Germany

For research use only. Not for use in diagnostic procedures. The Nucleofector<sup>™</sup> Technology is covered by patent and/or patent pending rights owned by the Lonza Group Ltd or its affiliates.

All trademarks belong to Lonza or its affiliates or to their respective third party owners. The information contained herein is believed to be correct and corresponds to the latest state of scientific and technical knowledge. However, no warranty is made, either expressed or implied, regarding its accuracy or the results to be obtained from the use of such information and no warranty is expressed or implied concerning the use of these products. The buyer assumes all risks of use and/or handling. Any user must make his own determination and satisfy himself that the products supplied by Lonza Group Ltd or its affiliates and the information and recommendations given by Lonza Group Ltd or its affiliates are (i) suitable for intended process or purpose, (ii) in compliance with environmental, health and safety regulations, and (iii) will not infringe any third party's intellectual property rights.

©2016 Lonza. All rights reserved. CD-BR019 02/16